4th Annual International Congress on Immunotherapies in Cancer: Focus on Practice-Changing Application is organized by Physicians' Education Resource, LLC (PER) and will be held on Dec 14, 2019 at InterContinental New York Times Square, New York, United States of America.
This educational program is directed toward oncologists, nurses, and pharmacists. Participants will be primarily those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on immunotherapies and their evolving roles in the treatment of patients with cancer.
The recent development of immunotherapies to treat cancer has transformed the way that clinicians think about managing their patients with many forms of malignancies. The speed at which basic science and clinical trial information continue to emerge in this area, however, creates practice and/or educational gaps for busy clinicians who strive to maintain state-of-the art care for their patients with cancer. This field is one of the most clinically relevant and exciting areas of novel drug development in oncology.
This exciting and fast-paced congress will provide a multi-module, curriculum-based program that focuses exclusively on immunotherapies and their application to the management of cancer. This intensive, 1-day interactive program will provide a comprehensive review of the key data sets that are most relevant to the application of these novel strategies for the clinician who manages some of the most difficult-to-treat forms of cancer. The program will focus on the practical application of recent clinical trial results that have shaped current and evolving clinical management, evolving biomarker information, the latest basic science findings, and the most highly anticipated clinical trials in the field.
Topics of particular interest will be optimal timing of checkpoint inhibitors, identification of patients with cell surface expression of a target antigen who would be good candidates for CAR T-cell treatment, using combination immunotherapies in patients with driver mutations (eg, EGFR/ALK), and the use of combination therapies targeting the IDO pathway in patients with advanced melanoma.
Upon successful completion of this educational activity, you should be better prepared to:
• Explain current and evolving mechanistic approaches concerning how the immune system can be targeted in the treatment of cancer
• Evaluate recent clinical trial findings on immuno-oncology strategies, and how they can be practically applied to the management of cancer in multiple lines of care
• Discuss emerging methods to personalize care via the use of biomarkers and other methods to individualize the use of immuno-oncology strategies
• Describe how common and uncommon adverse events, associated with the use of immuno-oncology strategies, can be proactively mitigated and managed
• Detail important remaining clinical questions in the field, and highly anticipated ongoing clinical trials, that are evaluating emerging immuno-oncology strategies
|Contact No. :||(888) 949-0045
|Registration Type||Last Date||Price|
|Physicians - Advance Fee||13 Dec,2019||USD 129.00|
|Fellows - Advance Fee||13 Dec,2019||USD 99.00|
|Nurses, PAs, Other Health Care Professionals - Advance Fee||13 Dec,2019||USD 99.00|
|Industry - Advance Fee||13 Dec,2019||USD 319.00|